AHU-377 hemicalcium salt is primarily used in pharmaceutical research and development as an active pharmaceutical ingredient (API) in the treatment of heart failure. It functions as a neprilysin inhibitor and is often combined with angiotensin receptor blockers to enhance cardiac function. This compound helps reduce blood pressure, decrease cardiac workload, and prevent the progression of myocardial damage. Its role in dual-acting medications improves patient outcomes by simultaneously targeting multiple pathways involved in cardiovascular regulation. Due to its efficacy, it is a key component in advanced heart failure therapies, particularly in drugs designed to improve survival and reduce hospitalization rates in patients with reduced ejection fraction.